Results 81 to 90 of about 1,153,662 (221)

In vitro thrombolytic potential of bioactive compounds from marine Streptomyces sp. VITJS4

Bioscience Journal, 2016
The most practical approach to reduce morbidity and mortality of coronary heart disease (CHD) is to delay the process of thrombus by usage of clot-dissolving agents. The necessities of such safer compounds are to be critically examined for thrombolytic 
S Jemimah Naine, C Subathra Devi, V Mohanasrinivasan   +2 more
doaj   +3 more sources

Effect of Fagonia Arabica (Dhamasa) on in vitro thrombolysis

BMC Complementary and Alternative Medicine, 2007
Background Atherothrombotic diseases such as myocardial or cerebral infarction are serious consequences of the thrombus formed in blood vessels. Thrombolytic agents are used to dissolve the already formed clots in the blood vessels; however, these drugs ...
Taori Girdhar M, Purohit Hemant J, Deopujari Jayant Y, Kashyap Rajpal, Prasad Sweta, Daginawala Hatim F   +5 more
doaj   +1 more source

Acrylonitrile adducts: design, synthesis and biological evaluation as antimicrobial, haemolytic and thrombolytic agent. [PDF]

Sci Rep, 2023
Das P, Devi N, Gaur N, Goswami S, Dutta D, Dubey R, Puzari A.   +6 more
europepmc   +1 more source

Mediators of the Association Between Stroke and Blood Cells: A Two‐Step Multivariable Mendelian Randomization Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
This study investigated the association and causality between complete blood count (CBC) parameters and stroke in 6736 participants from the 2011–2016 NHANES. Key CBC indices were identified as independent stroke predictors, with some showing significant nonlinear correlations with stroke events.
Tao Chen, Yan Li, Long Cai, Yijun Liu, Pengchen Kuang, Liuyi Zou, Ping Li   +6 more
wiley   +1 more source

Assessing the effectiveness of primary angioplasty compared with thrombolysis and its relationship to time delay: a Bayesian evidence synthesis [PDF]

, 2007
Background: Meta-analyses of trials have shown greater benefits from angioplasty than thrombolysis after an acute myocardial infarction, but the time delay in initiating angioplasty needs to be considered.
E. Fenwick, Palmer, Stephen, Sculpher, Mark, de Belder, Mark, Abrams, Keith R., Asseburg, Christian, Fenwick, E., M. Sculpher, K. R Abrams, C. Asseburg, de Belder, M., Vergel, Yolanda Bravo, Palmer, S., Assenburg, C., Abrams, K.R., Sculpher, M., M. de Belder, Y. Bravo Vergel, Bravo-Vergel, Y., S. Palmer, Fenwick, Elisabeth   +20 more
core   +1 more source

PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes.

PLoS ONE, 2016
Streptokinase (SK) remains a favored thrombolytic agent in the developing world as compared to the nearly 10-fold more expensive human tissue-plasminogen activator (tPA) for the dissolution of pathological fibrin clots in myocardial infarction.
Pooja Sawhney, Keya Katare, Girish Sahni
doaj   +1 more source

Constitutively active ADAMTS13: An emerging thrombolytic agent for acute ischemic stroke. [PDF]

J Thromb Haemost, 2022
Nayak MK, Flora GD, Chauhan AK.
europepmc   +1 more source

Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
The graphical abstract represents the underlying neuroprotective potential of ICS II against Alzheimer's disease, Cerebral ischemia and Parkinson disease. ICS II downregulates ROS production, inflammation, mitochondrial dysfunction and apoptosis along with regulating their key signalling pathways.
Ashutosh Solanki, Khushi Sharma, Jagrati Jain, Niraj Kumar Singh, Praveen T. Krishnamurthy   +4 more
wiley   +1 more source

Successful thrombolysis with low dose thrombolytic agent in a patient with acute life-threatening massive pulmonary thromboembolism: A case report. [PDF]

Ann Med Surg (Lond), 2022
Adhikari S, Vaidya N, Poudel P, Pathak S.   +3 more
europepmc   +1 more source

Intelligent design of artificial biocatalyst for biomedical diseases

Journal of Intelligent Medicine, Volume 3, Issue 3, Page 220-249, September 2026.
This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang, Nan Song, Huanhuan Qiao, Si Sun   +3 more
wiley   +1 more source